Calcium channel blockers for neuroleptic-induced tardive dyskinesia

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 11, 2011, Pages

  Essali, Adib ^a   Deirawan, Hany ^b   Soares Weiser, Karla ^c   Adams, Clive E ^d  

^a Modern Psychiatry Hospital   (Syrian Arab Republic)

^b Kalamoun University   (Syrian Arab Republic)

^c Enhance Reviews Ltd   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DILTIAZEM; NEUROLEPTIC AGENT; NIFEDIPINE; NIMODIPINE; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT;

DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HOSPITAL UTILIZATION; HUMAN; MENTAL HEALTH; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CALCIUM CHANNEL BLOCKERS; DYSKINESIA, DRUG-INDUCED; HUMANS; SCHIZOPHRENIA;

EID: 84860807689     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000206.pub3     Document Type: Review

References (72)

1. Alexander PE, Van Kammen DP, Bunney WE. Serum calcium and magnesium in schizophrenia: relationship to clinical phenomena and neuroleptic treatment. British Journal of Psychiatry 1978;133:143-9. [MEDLINE: 78236307; PUBMED: PMID 354732]
2. Brambilla F, Gessa GL, Sciascia A, Latina A, Maggioni M, Perna GP, Bondiolotti GP, Picotti G. Treatment of drug-resistant chronic schizophrenics with an association of neuroleptics and the calcium antagonist nimodipine. European Psychiatry 1992;7:177-82.
3. Dose M. The significance of calcium antagonists and anticonvulsants for the pharmacotherapy of psychoses [Die bedeutung von antikonvulsiva und calciumantagonisten fur die pharmakotherapie von psychosen]. Habilitationsschrift der Technischen Universitat Munchen 1991;1991:11-48. [MEDLINE: 97118626; PsycINFO: 1997-02370-004; PUBMED: 8959468]
4. Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in the treatment of tardive dyskinesia. Journal of Clinical Psychopharmacology 1990;10:414-6.
5. Fay-McCarthy M, Kendrick KA, Rosse RB, Schwartz BL, Peace T, Wyatt RJ, Deutsch SI. The effect of nifedipine on akathisia and agitation in patients with movement disorders. Schizophrenia Research 1997;24(1-2):208. [MEDLINE: 79229421; PMID: 37747]
6. Fay-McCarthy M, Kendrick KA, Rosse RB, Schwartz BL, Peace T, Wyatt RJ, Deutsch SI. The effect of nifedipine on tardive dyskinesia: a double blind study in eighteen patients. Schizophrenia Research 1997;24(1-2):271.
7. Leys D, Vermersch P, Danel T, Comayras S, Goudemand M, Caron J, Petit H. Diltiazem for tardive dyskinesia. Lancet 1988;1:250-1.
8. Loonen AJM, Verwey HA, Roels PR, van Bavel LP, Doorschot CH. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 1992;12:39-42.
9. Price WA, Pascarzi GA. Use of verapamil to treat negative symptoms in schizophrenia. Journal of Clinical Psychopharmacology 1987;7(5):357. [MEDLINE: 88059806; PMID: 3680609]
10. Ricketts RW, Singh NN, Ellis CR, Chambers S, Singh YN, Carmanico SJ, Vadney V, Cooke JC. Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation. Journal of Developmental and Physical Disabilities 1995;7(2):161-74.
11. Rzewuska M, Soucka K. Therapeutic effect of diltiazem in tardive dyskinesia. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 - Oct 4; Venice, Italy. 1995.
12. Schwartz BL, Fay McCarthy M, Kendrick K, Rosse RB, Deutsch SI. Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia. Clinical Neuropharmacology 1997;20(4):364-70.
13. Suddath RL, Straw GM, Freed WJ, Bigelow LB, Kirch DG, Wyatt RJ. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacology Biochemistry and Behavior 1991;39:743-5.
14. Yamada K, Kanba S, Ashikari I, Ohnishi K, Yagi G, Asai M. Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. Journal of Clinical Psychopharmacology 1996;16(6):437-9.
15. Yaryura, Krumholz, Wolpert, White, Merlis . Calcium as a proposed treatment for drug-induced extrapyramidal symptoms. Psychopharmacology Bulletin 1968;4(1):36-7. [: 14012]
16. Adler L, Duncan E, Reiter S, Angrist B, Peselow E, Rotrosen J. Effects of calcium-channel antagonists on tardive dyskinesia and psychosis. Psychopharmacology Bulletin 1988;24(3):421-5.
17. Falk WE, Wojick JD, Gelenberg AJ. Diltiazem for tardive dyskinesia and tardive dystonia. Lancet 1988;331(8589):824-5.
18. Alexander PE, Van-Kammen DP, Bunney WE Jr. Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms. Archives of General Psychiatry 1979;36:1372-7.
19. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
20. American Psychiatry Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992.
21. Barnes TRE, Edwards JG. Antipsychotic Drugs and their Side-Effects. London: Harcourt Brace & Company, 1993.
22. Barrow N, Childs A. An anti-tardive-dyskinesia effect of verapamil. American Journal of Psychiatry 1986;143(11):1485.
23. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.
24. Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD000205.pub2]
25. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
26. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
27. Buck OD, Havey P. Treatment of tardive dyskinesia with verapamil. Journal of Clinical Psychopharmacology 1988;8(4):303-4.
28. Casey DE. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ editor(s). Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1994.
29. Cates M, Lusk K, Wells BG, Gonzalez L, Parent M. Are calcium-channel blockers effective in the treatment of tardive dyskinesia?. Annals of Pharmacotherapy 1993;27:191-6.
30. Clarke M, Oxman AD. Cochrane Collaboration Handbook. The Cochrane Library. Oxford: Update Software, 2003. [: DNNVTD020600]
31. Curtin F, Altman D, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Statistics in Medicine 2002;21(15):2131-44. [MEDLINE: 22200087]
32. Curtin F, Elbourne D, Altman D. Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Statistics in Medicine 2002;21(15):2145-59. [MEDLINE: 22200088]
33. Curtin F, Elbourne D, Altman D. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Statistics in Medicine 2002;21(15):2161-73. [MEDLINE: 22200089]
34. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town. Cape Town: Cochrane Collaboration, 2000.
35. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
36. Dubovsky SL. Psychiatric application of calcium-channel blocking drugs. Today's Therapeutic Trends 1988;6:59-75.
37. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. [MEDLINE: 1997456606]
38. El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2]
39. Elbourne D, Altman D, Higgins J, Curtin F, Worthington H, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [MEDLINE: 21912237]
40. Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist 2003;9(1):1627.
41. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10. [PUBMED: 16360555]
42. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
43. Hendrickson JL, Ellis CR, Singh NN, Singh YN, Ricketts RW. Effects of calcium channel blockers on tardive dyskinesia. Journal of Developmental and Physical Disabilities 1994;6(2):125-36.
44. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
45. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
46. Hoerger M. The primacy of neuroleptic-induced D2 receptor hypersensitivity in tardive dyskinesia. Psychiatry Online 2007;13(12):18-26.
47. Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, Quay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
48. Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York: Guilford Press, 1982.
49. Jeste D, Caligiuri M. Tardive dyskinesia. Schizophrenia Bulletin 1993;19:303-16.
50. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
51. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
52. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
53. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
54. McGrath J, Soares-Weiser K. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000209.pub2]
55. Moher D, Schulz KF, Altman D, CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
56. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
57. Rathbone J, Deeks JJ, Soares-Weiser K. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD000203.pub3]
58. Rauchverger B, Isakov V, Jabarin M. Olanzapine-induced tardive dystonia successfully treated by tetrabenazine. Journal of Neuropsychiatry and Clinical Neurosciences 2007;19(4):4845.
59. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, Blank K, Koblenzer J, Kahaner K. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266(17):2402-6.
60. Schooler NR, Keith SJ. Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29:431-46.
61. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
62. Snyder SH, Reynolds IJ. Calcium-antagonist drugs: receptor interactions that clarify therapeutic effects. New England Journal of Medicine 1985;313:995-1002.
63. Soares K, McGrath J. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000204]
64. Soares-Weiser K, Joy C. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000208]
65. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2]
66. Stedman TJ, Whiteford HA, Eyles D, Welham JL, Pond SM. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. Journal of Clinical Psychopharmacology 1991;11:43-7.
67. Tammenmaa I, McGrath J, Sailas E, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD000207; MEDLINE: 22133093]
68. Tamminga CA, Woerner MG. Clinical course and cellular pathology of tardive dyskinesia. In: Davis KL, Charney D, Coyle JT, Nemeroff C editor(s). Neuropsychopharmacology: The Fifth Generation of Progress. American College of Neuropsychopharmacology, 2002:1831-41.
69. Wolf ME, Mosnaim AD (editors). Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. Washington, DC: American Psychiatric Press, 1988.
70. Xia J, Adams C, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y. Losing participants before trial ends erodes credibility of finding. Psychiatric Bulletin 2009;33(7):254-57.
71. Soares KV, McGrath JJ. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD000206; PUBMED: 11279683]
72. Soares-Weiser K, Rathbone J. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD000206.pub2; PUBMED: 14973950]